Pneumagen is using its platform technology, GlycoTarge, to develop glycan targeted carbohydrate-binding module domains (mCBMs) derived from bacterial glycosidases as a new universal therapeutic modality for the prevention and treatment of respiratory tract infections (RTIs). These engineered mCBMs have been shown to prevent and treat respiratory infections by binding to epithelial cell surface glycan receptors present in the respiratory tract, used by several pathogens for entry.